Abstract 236P
Background
Nasopharyngeal carcinoma is a disease unique to Southeast Asia. Radiotherapy and chemotherapy serve as the standard treatment mode for locally advanced nasopharyngeal carcinoma (LANPC), but the efficacy is not ideal due to local recurrence and distant metastasis. Meanwhile, studies have shown concurrent chemoradiotherapy will aggravate treatment-related side effects. Chrono-chemotherapy is to select the appropriate timing of administration according to the biological rhythm of the human body, in order to improve the efficacy and reduce side effects. At present, most studies on the treatment of LANPC by hourly chemotherapy combined with radiotherapy are single-center and small-sample studies, lacking evidence-based medical evidence. Therefore, we adopted the method of meta-analysis to evaluate the efficacy and safety of chemotherapy combined with radiotherapy for LANPC in existing studies, in order to provide reference for clinical treatment.
Methods
Seven databases were searched, including the Cochrane Library (Issue 5, 2021), Pubmed, Embase, CBM, CNKI, VIP and Wanfang Database. The meta-analysis was performed by the Revman 5.3 software.
Results
Thirteen studies containing 901 patients were finally included. Compared with the conventional chemotherapy group, results showed that the effective rate, adverse reactions and immune function of the chrono-chemotherapy group was significantly higher than that of the conventional chemotherapy group. Chrono-chemotherapy combined with radiotherapy can increase the effective rate (P<0.001), and the CD3, CD, CD4/CD8 were higher than the conventional chemotherapy group (P<0.001), at the same time, chrono-chemotherapy group cloud reduce the III-IV°leucopenia, thrombocytopenia, gastrointestinal reaction, oral mucosa reaction, radiothermitis (P<0.001).
Conclusions
Current evidence shows that compared with the conventional chemotherapy group, the chrono-chemotherapy with radiotherapy could improve the effective rate and immune function, and reduce adverse reactions at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03